Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Deloitte
Argus Health
Daiichi Sankyo
Express Scripts
Baxter
Cerilliant
Queensland Health
QuintilesIMS

Generated: June 21, 2018

DrugPatentWatch Database Preview

CILOSTAZOL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Cilostazol, and what generic alternatives are available?

Cilostazol is a drug marketed by Actavis Elizabeth, Apotex Inc, Breckenridge Pharm, Casi Pharms Inc, Chartwell Rx, Epic Pharma Llc, Frontida Biopharm, Ivax Sub Teva Pharms, Mylan, Mylan Pharms Inc, Pliva Hrvatska Doo, Teva, and West-ward Pharms Int. and is included in sixteen NDAs.

The generic ingredient in CILOSTAZOL is cilostazol. There are twelve drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cilostazol profile page.
Drug patent expirations by year for CILOSTAZOL
Pharmacology for CILOSTAZOL
Synonyms for CILOSTAZOL
2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-
2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-
2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril
73963-72-1
963C721
A837982
AB0012441
AB00382988_15
AB00382988_16
AB00382988-14
AB2000035
AC-4334
AC1L1EE2
ACT02663
AJ-26894
AK111532
AKOS015855512
AM90304
AN-12078
API0002016
BCP0726000145
BCP9000530
BCPP000279
BI7396
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRD-K67017579-001-17-4
BRN 3632107
BS0279
BSPBio_002759
C 0737
C-21103
C20H27N5O2
CAS-73963-72-1
CC-25783
CCG-39646
CHEBI:31401
CHEMBL799
Cilastatin sodium, Antibiotic for Culture Media Use Only
CILASTAZOL
Cilostazol (JP15/USAN/INN)
Cilostazol (JP17/USAN/INN)
Cilostazol [INN:JAN]
Cilostazol [USAN:USP:INN:BAN:JAN]
Cilostazol, >=98% (HPLC), powder
Cilostazol, pharmaceutical secondary standard; traceable to USP
Cilostazol, United States Pharmacopeia (USP) Reference Standard
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
CJ-24365
CL23867
CPD000058428
CS-1759
CTK8F0315
D01896
D03VPC
D0E7MJ
DB01166
DR002024
DSSTox_CID_25132
DSSTox_GSID_45132
DSSTox_RID_80693
DTXSID9045132
EU-0100218
FT-0602474
FT-0645036
GTPL7148
HE384746
HMS1922N15
HMS2093M14
HMS2096F16
HMS2234C06
HMS3260L17
HMS3268O09
HMS3654J13
HSDB 8312
HY-17464
J90029
KBio3_002259
KBioGR_001184
KM1582
KS-5154
Lopac-C-0737
Lopac0_000218
LP00218
LP108576
LS-142693
MCULE-8893820969
MFCD00866780
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
N7Z035406B
NCGC00015207-01
NCGC00015207-02
NCGC00015207-03
NCGC00015207-04
NCGC00015207-05
NCGC00015207-06
NCGC00015207-07
NCGC00015207-08
NCGC00015207-09
NCGC00015207-10
NCGC00015207-11
NCGC00015207-12
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
NCGC00260903-01
NSC-758936
NSC758936
OPC 13013
OPC 13013; OPC 21; Pletaal
OPC 21
OPC-13013
OPC-21
Opera_ID_488
OR13681
Otsuka brand of cilostazol
Pharmakon1600-01505230
Pleta (TN)
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
Q-200854
REGID_for_CID_2754
RP18108
RRGUKTPIGVIEKM-UHFFFAOYSA-N
s1294
SAM001246734
SAM001247085
SBI-0050206.P002
SC-14107
SCHEMBL16128
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
SR-01000003107
SR-01000003107-2
ST24046323
TC-063580
TL8005113
Tocris-1692
Tox21_110098
Tox21_110098_1
Tox21_500218
UNII-N7Z035406B
ZINC1552174
ZX-AFC000447
ZX-AT018851

US Patents and Regulatory Information for CILOSTAZOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Elizabeth CILOSTAZOL cilostazol TABLET;ORAL 077028-002 Nov 26, 2004 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc CILOSTAZOL cilostazol TABLET;ORAL 077019-002 Nov 23, 2004 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
West-ward Pharms Int CILOSTAZOL cilostazol TABLET;ORAL 077024-002 May 17, 2005 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Casi Pharms Inc CILOSTAZOL cilostazol TABLET;ORAL 077021-001 Nov 23, 2004 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Julphar
Federal Trade Commission
US Department of Justice
Argus Health
Baxter
McKinsey
Covington
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.